American CryoStem - America's Stem Cell Bank

1. American CryoStem Corporation; (CRYO) founded in 2008, has evolved to become a biotechnology pioneer,
standardizing adipose tissue derived technologies (Adult Stem Cells) for the fields of Regenerative and Personalized
Medicine. The Company operates a state-of-art, FDA-registered, clinical laboratory in Monmouth Junction, New Jersey
and licensed laboratories in Hong Kong, China and Tokyo, Japan, which operate on our proprietary platform, dedicated to
the collection, processing, bio-banking, culturing and differentiation of adipose tissue (fat) and adipose derived stem cells
(ADSCs) for current or future use in regenerative medicine. We are leveraging our strategic portfolio of intellectual
property (IP), our IRB approved, FDA compliant platform and a developed product portfolio to create a domestic and
global footprint of licensed laboratory affiliates, physicians networks, patients and research organizations who purchase
tissue collection, processing and storage consumables from our Company. Our laboratory stem cell products foundation
are characterized adult human Mesenchymal Stem Cell (MSC’s) derived from adipose tissue that work in conjunction
with our 13 patented (non-animal) xeno free medium lines. The Company’s R&D efforts are focused on university and
private collaborations to discover, develop and commercialize ADSC and laboratory products combined with synergistic
technologies to create jointly developed regenerative medicine applications and new intellectual property.
PROCESSCOLLECT STORE
ADIPOSE TISSUE
PROCEDURES
ADULT STEM CELL
PROCEDURES
ADULT STEM CELL
SKINCARE
HEALTHY-AGING (CELLULAR) PLATFORM
POSITIONED FOR GROWTH
We use our patented intellectual property to develop
safe and effective cellular medicine products and
applications for indications that represent a large unmet
need globally. Our therapeutic pipeline of products and
applications is based on technologies developed both
in-house and obtained through licensing and
collaboration arrangements with biotechnology
companies.
We intend to utilize our comprehensive Cellular platform
to support cellular products related to gender, age,
nationality, orthopedic applications and disease with
partners that can efficiently develop treatments without
having to rediscover and recreate the underlying
technology for each new product.
ABOUT THE COMPANY
INNOVATION
PLATFORM TECHONLOGY
PATIENT FOCUSED
An early adopter of utilizing adipose tissue as a stem
cell source we have designed every process and
product to standardize, validate and commercialize our
platform.
Patented, modular, platform technology allows
complete control of the stem cell processing and
manufacturing chain for optimal standardized cellular
characteristics.
Allowing a patient to improve their quality of life by
easily preparing for their current or future regenerative
medicine needs by utilizing our cellular platform with
multiple products, (bio-insurance) allowing for usage at
every stage of life.
American CryoStem Corporation 1 Meridian Road Eatontown, New Jersey 07724 | 732.747.1007 | jarnone@americancryostem.com

2. A STRATEGY FOR SUCCESS
Our strategy is aimed at offering a commercial platform to
allow individuals the opportunity to prepare for regenerative
/ personalized medicine by having their adipose derived
stem cells collected, processed and stored for current or
future use, harnessing the regenerative power of stem
cells to prevent and treat disease, repair damaged tissue
and provide natural cosmetic applications. As we age our
stem cells age, storing today locks in the individual’s
current biological age, preparing them for their medical
needs by utilizing our Healthy-Aging (cellular) stem cell
platform.
Our near term objectives are: to continue marketing our
cellular platform to physicians and individuals, continue to
market our products and services to corporate and
university researchers, expand our IP portfolio through in-
house development and joint ventures and to further
expand our international footprint through licensed
laboratories that purchase our consumable products.
OUR ROLE IN THE INDSUTRY
Regenerative & Personalized Medicine holds the promise of regenerating damaged tissues and organs in the body by
stimulating the body’s own repair mechanisms to heal previously irreparable tissues and organs. The industry currently
has three major categories where our platform and stem cell products participate;
Cell
Therapy
Autologous cell therapy: the use of
cells, from patients for the
treatment of diseases or injuries.
Applications may include arthritis,
heart disease, diabetes, MS,
Parkinson’s and Alzheimer’s
diseases, vision impairments,
orthopedic applications and brain
or spinal cord injuries.
Tissue
Engineering
Involves using a combination of
cells and biomaterials to re-
generate tissues and organs.
Therapeutic applications may
include bone re-growth, wound
healing, urinary tract repair, heart
repair, saphenous arterial grafts,
and spinal cord repair.
Diagnostics and Lab
Services
Involves the production of cell
lines used by clinicians and
researchers for the development
of treatments for diseases.
Services are targeted to
companies developing processes
that are designed for regenerative
medicine techniques, and
improving methods for the
extraction, processing, storage
and transportation of stem cells.

3. CELLECT™ Collection & Transportation
Patent-pending unbreakable “chain of custody” solution for
physicians to harvest fat tissue and deliver samples. The
Cellect™ service maintains the highest cell viability while
transporting the harvested tissue sample to the processing
laboratory.
ATGRAFT™ Adipose Tissue Storage
A service for physicians and individuals to cryopreserve
pure fat tissue as a natural biocompatible filler for cosmetic
layered fat grafting procedures without the trauma of
further liposuctions when visiting the physician for
additional procedures. One liposuction is the cornerstone
of our process. ATGRAFT™ procedures may include
breast augmentation, buttocks enhancement or volume
corrections in the hands, face and neck.
ATCELL™ Adipose Derived Stem Cells
(ADSCs)
Clinically processed ADSCs created using the
Company’s platform technology and patented cell
culture media(s). ATCELLs have the capability of
expanding into millions of cells and differentiated into
master cell lines for individual treatments or research
programs.
Chondrocytes
(Cartilage)
Differentiation Media Capabilities
OsteoblastsAdipocytes
(Fat)
ACSelerate™ Cell Culture Media Products
Patented (#7,989,205) - cell culture medium for the
growth of human adipose stromal cells for clinical and
therapeutic applications (including all cells found in human
skin, fat and other connective tissue) that is animal
product free. Optimization of differentiation medias is
currently on-going with research partners.
Cryopreserved fat tissue
Our platform OF REGENERATIVE products

4. This fact sheet may contain forward-looking statements, including information about management's view of American CryoStem Corporation’s (“the Company”) future expectations, plans and prospects. In particular, when used
in the preceding discussion, the words "believes," "expects," "intends," "plans," "anticipates," or "may," and similar conditional expressions are intended to identify forward-looking statements. Any statements made in this fact
sheet other than those of historical fact, about an action, event or development, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors, which may cause the results
of the Company, its subsidiaries and concepts to be materially different than those expressed or implied in such statements. Unknown or unpredictable factors also could have material adverse effects on the Company’s future
results. The forward-looking statements included in this fact sheet are made only as of the date hereof. The Company cannot guarantee future results, levels of activity, performance or achievements. Accordingly, you should
not place undue reliance on these forward-looking statements. Finally, the Company undertakes no obligation to update these statements after the date of this release, except as required by law, and also takes no obligation to
update or correct information prepared by third parties that are not paid for by American CryoStem Corporation.
• Strong “Picket-Fence” strategy IP portfolio of 17 foreign and
domestic patent applications and 2 issued patents centered around
collecting processing, storing and retrieving adipose tissue/stem
cell cellular products and laboratory processes addressing multi-
billion dollar markets.
• Global distribution through licensed laboratories of CRYO’s
products and applications (China, Hong Kong and Japan)
• FDA compliant product suite of regenerative products and
services.
• Ongoing relationships with leading stem cell universities and
private corporations that supports a pipeline of cellular products.
• Strong management and medical and scientific advisory board
comprised of leading scientists and physicians.
INVESTMENT HIGHLIGHTS
MANAGEMENT & MEDICAL & SCIENTIFIC ADVISORS*
John S. Arnone
Chairman & CEO
Anthony Dudzinski
Chief Operating Officer
John DiFolco
Executive Vice President
Ruth Goldman
VP & Laboratory Supervisor
Dr. Michael McGinnis*
Medical Laboratory Director
Dr. Vincent Giampapa, MD, FACS
Cosmetic Surgery Products
Dr. Dayong Gao*
Cryopreservation Expert
Dr. Burt Ensley*
Product Development
Dr. Richard Goldfarb*
Cosmetic Surgery
Dr. Roy D. Mittman*
Orthopedic Procedure Consulting
Dr. Frederic A. Stern*
Cosmetic Surgery, Clinical Study
Dr. Rand McClain, DO
Sports Medicine
COMPANY INFORMATION
Development OF A REGENERATIVE MEDICINE LEADER
2008
2010
2012
2014
2016
Identified Stem Cell
Type, developed
product concepts and
initial IP filings
Rented Lab Space, Collect,
Process & Store Platform
development additional IP
Filings
Constructed Clinical Lab, began
University collaborations additional
IP Filings, became fully reporting
public company
Initial marketing of completed
platform to physicians,
licensing transactions with
Hong Kong, Japan, China,
12 IP Filings
Integra Pharmaceuticals collaboration,
MS Clinical Study, treatment in Cayman
Islands and Costa Rica, Media
Licensing with Peprotech, Distribution
Partners - Cells on Ice